Ceragenix Pharmaceuticals to Present at the BIO 2006 Business Forum.DENVER -- Ceragenix Pharmaceuticals, Inc. ("Ceragenix"), a biopharmaceutical company focused on infectious disease and dermatology, today announced that Steven Porter, Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Ceragenix, will present at the BIO 2006 Business Forum on Tuesday, April 11 at 11:30 AM CDT CDT abbr. Central Daylight Time CDT Central Daylight Time CDT n abbr (US) (= Central Daylight Time) → hora de verano del centro; (BRIT in Room B of the McCormick Place Convention Center in Chicago. Mr. Porter will provide a brief corporate overview and discuss the company's novel anti-infective drugs--based on its proprietary class of compounds, Ceragenins (or CSAs)--and its Barrier Repair Technology. Ceragenix has submitted a 510K to the U.S. Food and Drug Administration seeking marketing clearance to commercialize its Barrier Repair Technology in 2006. About CERAGENIX Ceragenix Pharmaceuticals, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). : CGXP) is a biopharmaceutical company that discovers, develops and commercializes novel anti-infective drugs based on its proprietary class of compounds, Ceragenins (or CSAs). Active against a broad range of gram positive and negative bacteria, these agents are being developed as anti-infective medical device coatings and as therapeutics for antibiotic-resistant organisms. Ceragenix further owns exclusive rights to Barrier Repair Technology for the treatment of dermatological disorders including atopic dermatitis, neonatal skin disorders and others. Ceragenix's patented Barrier Repair Technology, invented by Dr. Peter Elias and licensed from the University of California The University of California has a combined student body of more than 191,000 students, over 1,340,000 living alumni, and a combined systemwide and campus endowment of just over $7.3 billion (8th largest in the United States). , is the platform for the development of two prescription topical creams--EpiCeram(R) and NeoCeram(R))--that form human-like skin barriers. Defects in the skin's barrier function play critical roles in the pathogenesis of skin diseases such as eczema, irritant contact dermatitis irritant contact dermatitis Occupational dermatology A form of CD that usually affects the hands and arms, caused by acids, alkalis; the intensity of skin response reflects intrinsic nature of the chemical, its concentration, and duration of contact Clinical and other common skin disorders and may also be of importance in HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. related skin dermatoses. Ceragenix has submitted a 510K to the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. seeking marketing clearance to commercialize this technology in 2006. For additional information on Ceragenix, please visit www.ceragenix.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion